Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual MeetingGlobeNewsWire • 04/29/25
Affimed Announces Acceptance of Three Abstracts for Presentation at the American Society for Clinical Oncology Annual MeetingGlobeNewsWire • 04/23/25
Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price RequirementGlobeNewsWire • 04/21/25
Affimed Announces Acceptance of AFM24 Abstract on Dose Optimization for Presentation at American Association for Cancer Research Annual MeetingGlobeNewsWire • 03/25/25
Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)GlobeNewsWire • 12/09/24
Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung CancerGlobeNewsWire • 12/09/24
Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) PatientsGlobeNewsWire • 12/08/24
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)GlobeNewsWire • 12/05/24
Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024GlobeNewsWire • 11/06/24
Affimed Follow Up: Upcoming Acimtamig And AFM24 Updates Could Be Positive CatalystsSeeking Alpha • 09/04/24
Affimed to Report Second Quarter 2024 Financial Results & Corporate Update on September 5, 2024GlobeNewsWire • 08/29/24